Danielle Greenawalt

机构：Bristol-Myers Squibb (United States) · ORCID：0000-0002-6297-0753

发表论文 69 篇 · 总被引 2633 次 · h-index 12

代表论文

• Prognostic Significance and Biologic Associations of Senescence‐Associated Secretory Phenotype Biomarkers in Heart Failure (2024 · Journal of the American Heart Association · 被引 23)
• Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies (2024 · Clinical Cancer Research · 被引 16)
• Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer (2026 · Journal for ImmunoTherapy of Cancer · 被引 4)
• Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study (2025 · ESMO Open · 被引 1)
• Supplementary Tables S1-S22 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies (2025)
• Supplementary Figure S3 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies (2025)